drugset / Trial / NCT01038687
Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
Phase 2
Completed
36 enrolled
Michael Camilleri, MD
National Center for Research Resources (NCRR) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-01
- Completion
- 2011-01
Publications
- Results Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011 Dec;106(12):2154-64. doi: 10.1038/ajg.2011.285. Epub 2011 Aug 30.
- Rudling M, Camilleri M, Graffner H, Holst JJ, Rikner L. Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord. 2015 Jul 22;15:75. doi: 10.1186/s12872-015-0070-9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elobixibat | Small molecule | 15 mg | Oral |
| Subject | Elobixibat | Small molecule | 20 mg | Oral |